Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04944784 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 3 study, sponsored by Cytokinetics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 489
- Enrollment target
NCT04944784: Clinical Trial Phase 3 study, sponsored by Cytokinetics.
NCT04944784 is a Phase 3 study that was terminated before completion, run by Cytokinetics. The registered enrollment target is 489 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04944784, a Phase 3 study, was terminated before completion, sponsored by Cytokinetics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 489 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
Primary Outcome
Change from baseline to Week 24 in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score using MMRM without multiple imputation; rating scale 0 to 48; higher scores indicate better functional status
Interventions
- DRUG Placebo
- DRUG Reldesemtiv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2023-07-18 |
| Phase | Phase 3 |
Why NCT04944784 stopped before completion
NCT04944784 is an interventional study that assigns participants to a tested intervention. The registered 489 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04944784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04944784 about?
NCT04944784 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.
What is the current status of trial NCT04944784?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 489 participants. The study started on 2021-08-16. Estimated completion is 2023-07-18.
What interventions are being tested in trial NCT04944784?
The interventions under investigation include: Placebo (DRUG), Reldesemtiv (DRUG).
Who is sponsoring clinical trial NCT04944784?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04944784's enrollment target sits among peer trials
489 783rd of 2000 higher than 1,217 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI